Contact:
Mark Scharmann
bioethicsltd@gmail.com
(801) 399-3632
One-Line Pitch:
SILQ’s patented, FDA-approved smooth surface coating technology reduces infections and pain associated with implantable medical devices while also decreasing healthcare costs and supporting applications across multiple industries.
Market & Technology Summary:
Hospital-acquired infections (HAIs) contribute significantly to healthcare costs ($34–$74 billion annually). SILQ’s coating prevents biofilm bacteria on implantable devices, receiving FDA clearance for the ClearTract® Foley Catheter and other bladder and kidney applications. Potential uses extend to contact lenses, water treatment, and microfluidic devices.
Product Description:
SILQ's coating is applied to finished device surfaces or membranes and does not require a specialized environment. A prototype coating device is available for research and scalability.
Market Traction and Proof Points:
Early adoption by Los Angeles County Department of Health (LADHS) has led to nationwide distribution. The ClearTract® Foley Catheter received an Innovative Technology contract from Vizient, granting access to 5,000 hospitals and clinics. SILQ plans to expand its market presence via an internal salesforce and distributors.
Technology Applications:
- Medical: Urinary catheters, pacemaker leads, GI tubes, endotracheal tubes, breast implants, etc.
- Industrial: Water treatment membranes, hydroponics, non-woven fabric, etc.
- Consumer Goods: Wearable electronics, cell phone cases.
- Biotech: Microfluidics, mRNA vaccine production, lab consumables.
Competition:
SILQ outperforms competitors with its ClearTract® catheter, reducing biofilm by over 2.5 times compared to Bard’s silver-coated catheter. Other competitors offer commodity products, but SILQ positions itself to dominate with its unique technology.
IP Summary:
SILQ holds five patent families (21 pending applications) covering methods, compounds, and applications, with patents granted or pending in major global markets. Proprietary trade secrets enhance its manufacturing and purification methods.
Problems to Solve/Markets to Disrupt:
SILQ reduces HAIs and eases implant/extraction pain, combating antibiotic-resistant superbugs. Its technology promises advancements in contact lens comfort, biofouling prevention, and microfluidic performance.
Business Model:
SILQ targets high-potential markets for surface-treatment products, including healthcare, biotech, industrial, and consumer goods, representing billions in revenue opportunities.
Financial Projections (USD):
Revenues projected to grow from $450,000 in 2024 to over $540 million by 2030. EBITDA is expected to reach $205.8 million by 2030.
Merger and Securities Offering:
SILQ has a definitive merger agreement with Bioethics, LTD., which includes raising $5.5 million through a private placement to expand its operations and market reach.
Ready to Ask For Funding for your company?
Post a Funding Request